National Healthcare Quality and Disparities Report
Latest available findings on quality of and access to health care
Data
- Data Infographics
- Data Visualizations
- Data Tools
- Data Innovations
- All-Payer Claims Database
- Healthcare Cost and Utilization Project (HCUP)
- Medical Expenditure Panel Survey (MEPS)
- AHRQ Quality Indicator Tools for Data Analytics
- State Snapshots
- United States Health Information Knowledgebase (USHIK)
- Data Sources Available from AHRQ
Search All Research Studies
AHRQ Research Studies
Sign up: AHRQ Research Studies Email updates
Research Studies is a compilation of published research articles funded by AHRQ or authored by AHRQ researchers.
Results
1 to 2 of 2 Research Studies DisplayedDesai SM, McWilliams JM
340B Drug Pricing Program and hospital provision of uncompensated care.
This study evaluated whether hospital entry into the 340B Drug Pricing Program is associated with changes in hospital provision of uncompensated care. The authors analyzed secondary data on 340B participation and uncompensated care provision among general acute care hospitals and critical access hospitals from 2003 to 2015. They constructed an annual, hospital-level data set on hospital 340B participation and on uncompensated care provision. They did not find evidence that hospitals increased provision of uncompensated care after entry into the 340B program differentially more than hospitals that never entered or had not yet entered the program.
AHRQ-funded; HS026980; HS024072.
Citation: Desai SM, McWilliams JM .
340B Drug Pricing Program and hospital provision of uncompensated care.
Am J Manag Care 2021 Oct;27(10):432-37. doi: 10.37765/ajmc.2021.88761..
Keywords: Hospitals, Healthcare Costs, Medication
Desai S, McWilliams JM
Consequences of the 340B drug pricing program.
Researchers used Medicare claims and a regression-discontinuity design, taking advantage of the threshold for program eligibility among general acute care hospitals to isolate the effects of the 340B Drug Pricing Program on hospital-physician consolidation and on the outpatient administration of parenteral drugs. They concluded that the Program has been associated with hospital-physician consolidation in hematology-oncology and with more hospital-based administration of parenteral drugs in hematology-oncology and ophthalmology.
AHRQ-funded; HS024072.
Citation: Desai S, McWilliams JM .
Consequences of the 340B drug pricing program.
N Engl J Med 2018 Feb 8;378(6):539-48. doi: 10.1056/NEJMsa1706475.
.
.
Keywords: Healthcare Costs, Payment, Hospitals, Medicare, Medication